Use of radionuclides in metastatic prostate cancer: pain relief and beyond

Salil Vengalil; Joe M O'Sullivan; Christopher C Parker

doi:10.1097/SPC.0b013e328355e082

Use of radionuclides in metastatic prostate cancer: pain relief and beyond

Salil Vengalil, Joe M O'Sullivan, Christopher C Parker

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Bone metastases in prostate cancer are often the cause of significant morbidity in patients with castrate-resistant disease, and several studies have shown significant pain palliation with systemic radionuclide treatment. The purpose of this review is to discuss the place of radionuclides in the dynamic treatment landscape of metastatic prostate cancer in light of new evidence demonstrating benefit beyond palliation.

Original language	English
Pages (from-to)	310-5
Number of pages	6
Journal	Current opinion in supportive and palliative care
Volume	6
Issue number	3
DOIs	https://doi.org/10.1097/SPC.0b013e328355e082
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/SPC.0b013e328355e082

Cite this

@article{de8e49f4270f4c72a6ad34825106a9ae,

title = "Use of radionuclides in metastatic prostate cancer: pain relief and beyond",

abstract = "Bone metastases in prostate cancer are often the cause of significant morbidity in patients with castrate-resistant disease, and several studies have shown significant pain palliation with systemic radionuclide treatment. The purpose of this review is to discuss the place of radionuclides in the dynamic treatment landscape of metastatic prostate cancer in light of new evidence demonstrating benefit beyond palliation.",

author = "Salil Vengalil and O'Sullivan, {Joe M} and Parker, {Christopher C}",

year = "2012",

doi = "10.1097/SPC.0b013e328355e082",

language = "English",

volume = "6",

pages = "310--5",

journal = "Current opinion in supportive and palliative care",

issn = "1751-4258",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Use of radionuclides in metastatic prostate cancer

T2 - pain relief and beyond

AU - Vengalil, Salil

AU - O'Sullivan, Joe M

AU - Parker, Christopher C

PY - 2012

Y1 - 2012

N2 - Bone metastases in prostate cancer are often the cause of significant morbidity in patients with castrate-resistant disease, and several studies have shown significant pain palliation with systemic radionuclide treatment. The purpose of this review is to discuss the place of radionuclides in the dynamic treatment landscape of metastatic prostate cancer in light of new evidence demonstrating benefit beyond palliation.

AB - Bone metastases in prostate cancer are often the cause of significant morbidity in patients with castrate-resistant disease, and several studies have shown significant pain palliation with systemic radionuclide treatment. The purpose of this review is to discuss the place of radionuclides in the dynamic treatment landscape of metastatic prostate cancer in light of new evidence demonstrating benefit beyond palliation.

U2 - 10.1097/SPC.0b013e328355e082

DO - 10.1097/SPC.0b013e328355e082

M3 - Article

C2 - 22710580

SN - 1751-4258

VL - 6

SP - 310

EP - 315

JO - Current opinion in supportive and palliative care

JF - Current opinion in supportive and palliative care

IS - 3

ER -

Use of radionuclides in metastatic prostate cancer: pain relief and beyond

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this